Contineum Therapeutics, Inc. cash flow to debt ratio of -670.45% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Contineum Therapeutics, Inc.'s free cash flow has decreased 66.50% from $-33.36M last year to $-55.54M, signaling decreasing performance

Contineum Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Contineum Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.03 last year to 0.03 today, signaling strengthened financials

Contineum Therapeutics, Inc. has a net cash position, so leverage is healthy.

Contineum Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Contineum Therapeutics, Inc. has insufficient data to evaluate this check.

Contineum Therapeutics, Inc.'s short-term assets of $267.92M exceed its short-term liabilities of $9.74M

Contineum Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Contineum Therapeutics, Inc.'s return on equity of -24.73%, is lower than 15.00%, indicating bad performance

Contineum Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Contineum Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Contineum Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Contineum Therapeutics, Inc. has negative free cash flow, indicating cash burn

Contineum Therapeutics, Inc.'s yearly earnings has decreased 41.93% since last year from $-42.26M to $-59.98M, signaling decreasing performance

Contineum Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -26.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Contineum Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Contineum Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Contineum Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Contineum Therapeutics, Inc. has insufficient data to evaluate this check.

Contineum Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Contineum Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Contineum Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Contineum Therapeutics, Inc. has insufficient data to evaluate this check.

Contineum Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Contineum Therapeutics, Inc. has a price-to-book ratio of 2.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Contineum Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue